This compound is a statin metabolite impurity, specifically a quinoline derivative with a cyclopropyl and fluorophenyl substituent. It is primarily used as a reference standard or impurity marker in pharmaceutical manufacturing and quality control.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 222306-15-2
Carbimazole
pharmaceutical raw material
(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-hydroxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide
pharmaceutical raw material
(S,E)-N-(4-((3,4-Difluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide (Afatinib Impurity)
pharmaceutical raw material
(S,E)-N-(4-((3,4-Dichlorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide (Afatinib Impurity)
pharmaceutical raw material
Pitavastatin sodium
pharmaceutical raw material
Pitavastatin calcium
pharmaceutical raw material
(E)-3-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl-2-propenal
pharmaceutical intermediate
2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxaldehyde
pharmaceutical intermediate
(E,3R)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3-hydroxy-5-oxohept-6-enoic acid
GSCOCVOFYBEZGB-TZZQJPOUSA-N
C1CC1C2=NC3=CC=CC=C3C(=C2/C=C/C(=O)C[C@H](CC(=O)O)O)C4=CC=C(C=C4)F